Back

Pro-atherogenic monocytes as risk prediction marker for severe coronary artery disease in post-menopausal women

30 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Sex differences (1) Cardiovascular Risk Assessment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mrs Julia Kielb

University Hospital of Duesseldorf, Duesseldorf (Germany)

5 More presentations in this session

Presentation thumbnail
Gender affects care and prognosis in acute coronary syndrome
Doctor C. Sari (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Maternal and fetal outcomes of various lipid-lowering treatment regimens during pregnancy: insights from the czech national registry 2012-2023
Doctor P. Jadrnickova (Ostrava, CZ)
Abstract Slides Video
Presentation thumbnail
Distinctions in cell biosynthesis and fuel oxidation between sexes are linked to better left ventricular global longitudinal strain in older women.
Doctor M. Aw (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Sex differences in physical activity trajectories and risks for adverse outcomes in patients with implantable cardioverter defibrillators
Doctor A. Gaffey (New Haven, US)
Abstract Slides Video
Presentation thumbnail
Sex-specific association of coagulation factor XI with 2-year cardiovascular outcomes in multivessel coronary artery disease: insights into a paradoxical cardioprotective role
Miss K. Zhang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Sex differences (1)

The Event

Event poster

ESC Congress 2025

30 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Session
Cardiovascular risk in women
thumbnail
Congress Presentation
Angina pectoris after coronary angiography or revascularization in pre- and postmenopausal women with coronary artery disease
thumbnail
Congress Presentation
Menopause timing and cardiovascular health: an individual participant data and literature-based meta-analysis of 13 studies and 22,249 postmenopausal women

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources